12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PX-866: Interim Phase II data

Interim data from 15 evaluable patients with GBM at first recurrence in a 2-stage, single-arm, open-label, Canadian Phase II trial showed that 12 patients discontinued therapy after receiving a median of one 8-week cycle of once-daily 8 mg oral PX-866. Of the discontinuations, 9 were due to...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >